PMID- 28980085
OWN - NLM
STAT- MEDLINE
DCOM- 20180808
LR  - 20181113
IS  - 1434-9949 (Electronic)
IS  - 0770-3198 (Linking)
VI  - 37
IP  - 2
DP  - 2018 Feb
TI  - Real-world experience of tocilizumab in rheumatoid arthritis: sub-analysis of 
      data from the Italian biologics' register GISEA.
PG  - 315-321
LID - 10.1007/s10067-017-3846-8 [doi]
AB  - To assess the long-term effectiveness and safety of tocilizumab, abatacept, and 
      tumor necrosis factor-alpha inhibitors (TNFi), in the Italian real-world setting of 
      rheumatoid arthritis (RA). The records of adult RA patients from the Italian 
      biologics' registry Gruppo Italiano Studio Early Arthritis (GISEA) were analyzed. 
      Demographic and clinical data were obtained at entry. The disease remission rate 
      (28-joint disease activity score calculated using the erythrocyte sedimentation 
      rate [DAS28-ESR] </= 2.6) and frequency of adverse events (AEs) were evaluated at 
      2 years. From 1999 to 2014, 7539 patients were treated with biologics (61.3% in 
      first- and 22.6% in second-line), 68% of cases received TNFi, 9.1% tocilizumab, 
      and 8.6% abatacept. Treatment groups showed a similar DAS28 at entry. As 
      first-line, tocilizumab induced a significantly higher remission rate than 
      abatacept or TNFi at 6 (51 vs 23.3 and 26.2%, respectively; p < 0.0001) and 
      24 months (52.3 vs 33.3 and 34.4%, respectively; p < 0.01). A similar pattern was 
      observed in later lines. The most common AEs reported were infections, reactions 
      to biologics (more frequent among TNFi-treated patients), increased transaminase 
      (more frequent among TCZ-treated patients), and cardiovascular events. In 
      clinical practice, TCZ induced a rapid and long-lasting remission and in a higher 
      percentage of patients compared to abatacept and TNFi, with a good safety 
      profile.
FAU - Iannone, F
AU  - Iannone F
AD  - Rheumatology Unit, Department of Emergency Medicine and Transplantation, 
      University of Bari, Bari, Italy. florenzo.iannone@uniba.it.
AD  - Rheumatology Unit, Interdisciplinary Department of Medicine, University of Bari, 
      P.zza G. Cesare 11, 70124, Bari, Italy. florenzo.iannone@uniba.it.
FAU - Ferraccioli, G
AU  - Ferraccioli G
AD  - Institute of Rheumatology and Affine Sciences, Catholic University of the Sacred 
      Heart, Rome, Italy.
FAU - Sinigaglia, L
AU  - Sinigaglia L
AD  - Department of Rheumatology, Gaetano Pini Institute, Milan, Italy.
FAU - Favalli, E G
AU  - Favalli EG
AD  - Department of Rheumatology, Gaetano Pini Institute, Milan, Italy.
FAU - Sarzi-Puttini, P
AU  - Sarzi-Puttini P
AD  - L. Sacco University Hospital, Milan, Italy.
FAU - Atzeni, F
AU  - Atzeni F
AD  - L. Sacco University Hospital, Milan, Italy.
FAU - Gorla, R
AU  - Gorla R
AD  - Rheumatology and Clinical Immunology Unit, Spedali Civili di Brescia, Brescia, 
      Italy.
FAU - Bazzani, C
AU  - Bazzani C
AD  - Rheumatology and Clinical Immunology Unit, Spedali Civili di Brescia, Brescia, 
      Italy.
FAU - Govoni, M
AU  - Govoni M
AD  - Department of Medical Science, Section of Rheumatology, University of Ferrara and 
      Azienda Ospedaliero Universitaria Sant'Anna di Cona, Ferrara, Italy.
FAU - Farina, I
AU  - Farina I
AD  - Department of Medical Science, Section of Rheumatology, University of Ferrara and 
      Azienda Ospedaliero Universitaria Sant'Anna di Cona, Ferrara, Italy.
FAU - Gremese, E
AU  - Gremese E
AD  - Institute of Rheumatology and Affine Sciences, Catholic University of the Sacred 
      Heart, Rome, Italy.
FAU - Carletto, A
AU  - Carletto A
AD  - Rheumatology Unit, University of Verona, Verona, Italy.
FAU - Giollo, A
AU  - Giollo A
AD  - Rheumatology Unit, University of Verona, Verona, Italy.
FAU - Galeazzi, M
AU  - Galeazzi M
AD  - Rheumatology Unit, University of Siena, Siena, Italy.
FAU - Foti, R
AU  - Foti R
AD  - Rheumatology Unit, A.O.U. Policlinico Vittorio Emanuele, Catania, Italy.
FAU - Bianchino, L
AU  - Bianchino L
AD  - Roche Spa, Monza, Italy.
FAU - La Grasta, L
AU  - La Grasta L
AD  - Roche Spa, Monza, Italy.
FAU - Lapadula, G
AU  - Lapadula G
AD  - Rheumatology Unit, Department of Emergency Medicine and Transplantation, 
      University of Bari, Bari, Italy.
LA  - eng
GR  - no grant number/Roche S.p.A. Italy/
PT  - Journal Article
DEP - 20171005
PL  - Germany
TA  - Clin Rheumatol
JT  - Clinical rheumatology
JID - 8211469
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Antirheumatic Agents)
RN  - 0 (Biological Products)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 7D0YB67S97 (Abatacept)
RN  - I031V2H011 (tocilizumab)
SB  - IM
MH  - Abatacept/adverse effects/therapeutic use
MH  - Adult
MH  - Antibodies, Monoclonal, Humanized/adverse effects/*therapeutic use
MH  - Antirheumatic Agents/adverse effects/*therapeutic use
MH  - Arthritis, Rheumatoid/*drug therapy
MH  - Biological Products/adverse effects/*therapeutic use
MH  - Female
MH  - Humans
MH  - Italy
MH  - Male
MH  - Middle Aged
MH  - Registries
MH  - Remission Induction/methods
MH  - Treatment Outcome
MH  - Tumor Necrosis Factor-alpha/antagonists & inhibitors
OTO - NOTNLM
OT  - Biologics
OT  - Italy
OT  - Real-world
OT  - Registry
OT  - Rheumatoid arthritis
OT  - Tocilizumab
EDAT- 2017/10/06 06:00
MHDA- 2018/08/09 06:00
CRDT- 2017/10/06 06:00
PHST- 2017/04/10 00:00 [received]
PHST- 2017/09/18 00:00 [accepted]
PHST- 2017/08/31 00:00 [revised]
PHST- 2017/10/06 06:00 [pubmed]
PHST- 2018/08/09 06:00 [medline]
PHST- 2017/10/06 06:00 [entrez]
AID - 10.1007/s10067-017-3846-8 [pii]
AID - 10.1007/s10067-017-3846-8 [doi]
PST - ppublish
SO  - Clin Rheumatol. 2018 Feb;37(2):315-321. doi: 10.1007/s10067-017-3846-8. Epub 2017 
      Oct 5.